# Alignment Healthcare, Inc.: overview

ALHC · Nasdaq · CIK 1832466 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/alhc.md) · [Financials](/companies/alhc/financials.md) · [Filings](/companies/alhc/filings.md) · [Insiders](/companies/alhc/insiders.md)

Latest reported revenue: [$1.36bn](/filings/0001628280-26-068247.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 29, 2026 (XBRL us-gaap:Revenues, accession 0001628280-26-068247).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [701 d](/filings/0001628280-26-012545.md) | [927](/filings/0001628280-26-028901.md) | [1,015](/filings/0001628280-26-051060.md) | [994](/filings/0001628280-26-068247.md) | [1,013 d](/filings/0001628280-26-012545.md) | [1,235](/filings/0001628280-26-028901.md) | [1,336](/filings/0001628280-26-051060.md) | [1,358](/filings/0001628280-26-068247.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(3.2%) d](/filings/0001628280-26-012545.md) | [(0.6%)](/filings/0001628280-26-028901.md) | [2.2%](/filings/0001628280-26-051060.md) | [0.8%](/filings/0001628280-26-068247.md) | [(1.0%) d](/filings/0001628280-26-012545.md) | [1.3%](/filings/0001628280-26-028901.md) | [3.2%](/filings/0001628280-26-051060.md) | [(0.3%)](/filings/0001628280-26-068247.md) |
| Net margin | % | [(4.4%) d](/filings/0001628280-26-012545.md) | [(1.0%)](/filings/0001628280-26-028901.md) | [1.5%](/filings/0001628280-26-051060.md) | [0.4%](/filings/0001628280-26-068247.md) | [(1.1%) d](/filings/0001628280-26-012545.md) | [0.9%](/filings/0001628280-26-028901.md) | [2.7%](/filings/0001628280-26-051060.md) | [(0.6%)](/filings/0001628280-26-068247.md) |
| Diluted EPS | $ per share | not reported | [(0.05)](/filings/0001628280-26-028901.md) | [0.07](/filings/0001628280-26-051060.md) | [0.02](/filings/0001628280-26-068247.md) | not reported | [0.05](/filings/0001628280-26-028901.md) | [0.17](/filings/0001628280-26-051060.md) | [(0.04)](/filings/0001628280-26-068247.md) |
| Free cash flow | $m | [(18.0) d](/filings/0001628280-26-012545.md) | [8.4](/filings/0001628280-26-028901.md) | [21.1 d](/filings/0001628280-26-051060.md) | [139 d](/filings/0001628280-26-068247.md) | [(55.4) d](/filings/0001628280-26-012545.md) | [121](/filings/0001628280-26-028901.md) | [(27.5) d](/filings/0001628280-26-051060.md) | [38.6 d](/filings/0001628280-26-068247.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,167](/filings/0000950170-24-021154.md) | [1,432](/filings/0000950170-24-021154.md) | [1,801](/filings/0000950170-24-021154.md) | [2,704](/filings/0001628280-26-012545.md) | [3,949](/filings/0001628280-26-012545.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(15.3%)](/filings/0000950170-24-021154.md) | [(9.0%)](/filings/0001628280-25-008730.md) | [(7.1%)](/filings/0001628280-26-012545.md) | [(3.8%)](/filings/0001628280-26-012545.md) | [0.4%](/filings/0001628280-26-012545.md) |
| Net margin | % | [(16.7%)](/filings/0000950170-24-021154.md) | [(10.4%)](/filings/0001628280-25-008730.md) | [(8.2%)](/filings/0001628280-26-012545.md) | [(4.7%)](/filings/0001628280-26-012545.md) | [(0.0%)](/filings/0001628280-26-012545.md) |
| Diluted EPS | $ per share | [(1.14)](/filings/0000950170-24-021154.md) | [(0.83)](/filings/0001628280-25-008730.md) | [(0.79)](/filings/0001628280-26-012545.md) | [(0.67)](/filings/0001628280-26-012545.md) | [0.00](/filings/0001628280-26-012545.md) |
| Free cash flow | $m | not reported | [(69.2)](/filings/0001628280-25-008730.md) | [(95.2)](/filings/0001628280-26-012545.md) | [(6.6)](/filings/0001628280-26-012545.md) | [113](/filings/0001628280-26-012545.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/alhc/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $460.6m | 19,342,956 |  | Added +5,267,759 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $447.2m | 18,780,363 |  | Added +1,681,427 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $331.5m | 13,924,329 |  | Reduced −1,967,735 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $277.9m | 11,672,259 |  | Added +1,962,188 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $246.8m | 10,365,640 |  | Added +3,365,541 |
| [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $222.5m | 9,346,742 |  | Added +6,131,075 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $193.9m | 8,144,247 |  | Added +170,584 |
| [WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC](/funds/1644956.md) | 2026-06-30 | $184.8m | 7,761,403 |  | Added +2,546,789 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $173.8m | 7,297,494 |  | Added +3,003,800 |
| [Hood River Capital Management LLC](/funds/1578177.md) | 2026-06-30 | $147.3m | 6,184,526 |  | Added +130,049 |

## Recent filings

[All 809 filings](/companies/alhc/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 16:15 ET | [10-Q](/filings/0001628280-26-068247.md) | Quarterly report, period 2026-09-30 | 0001628280-26-068247 |
| 2026-10-29 | 16:01 ET | [8-K](/filings/0001171843-26-006971.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-006971 |
| 2026-10-08 | 17:13 ET | [8-K](/filings/0001628280-26-065470.md) | 7.01 Regulation FD disclosure | 0001628280-26-065470 |
| 2026-07-30 | 16:14 ET | [10-Q](/filings/0001628280-26-051060.md) | Quarterly report, period 2026-06-30 | 0001628280-26-051060 |
| 2026-07-30 | 16:01 ET | [8-K](/filings/0001171843-26-005078.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-005078 |
| 2026-06-09 | 16:31 ET | [8-K](/filings/0001628280-26-041926.md) | 5.07 Shareholder vote results | 0001628280-26-041926 |
| 2026-05-12 | 16:33 ET | [8-K](/filings/0001628280-26-034147.md) | 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure | 0001628280-26-034147 |
| 2026-04-30 | 16:14 ET | [10-Q](/filings/0001628280-26-028901.md) | Quarterly report, period 2026-03-31 | 0001628280-26-028901 |
| 2026-04-30 | 16:01 ET | [8-K](/filings/0001171843-26-002895.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-002895 |
| 2026-04-24 | 10:52 ET | [DEF 14A](/filings/0001628280-26-027058.md) | Proxy statement, period 2026-06-04 | 0001628280-26-027058 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-012545.md), filed Feb 27, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures. [See the target](/leagues/2026q3/targets/5dfa3846-f9da-40ca-a8b7-9a4032876640)

## About the filer

- CIK: 1832466
- Tickers: ALHC
- Exchange: Nasdaq
- SIC code: 6324 Hospital & Medical Service Plans
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 18:01 ET. No prices; not investment advice.